Under construction – not a live service
Sign in
Taking people in SpainNo phase

Studying adults with essential thrombocythemia who later develop polycythemia vera

Looks back at adults with essential thrombocythemia who later develop polycythemia vera.

Plain-language title generated from the registry record
Registry title: A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes

Key facts

Where
Barcelona and Madrid, SpainSee the 2 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Source: NCT07203768, who can take part

Where in Spain

  • IDIBAPS, Hospital clinicBarcelona, SpainTaking people
  • 12 Octubre University HospitalMadrid, SpainTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Trial code
NCT07203768
Record updated
9 July 2026
Original description
International multicenter retrospective observational study consisting of two parts: a nested case-control study (part A) and a comparative retrospective cohort study (part B).Read full original descriptionShow less

Unmasking Polycythemia Vera in Long-Standing Essential Thrombocythemia: A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes

International multicenter retrospective observational study consisting of two parts: a nested case-control study (part A) and a comparative retrospective cohort study (part B).

Inclusion: ET patients (diagnosed according to "International consensus classification of myeloid neoplasms and acute leukemias - 2022" criteria) who are JAK2V617F positive and have progressed to PV (diagnosed according to "International consensus classification of myeloid neoplasms and acute leukemias - 2022" criteria) by 31/12/2020. The date of PV diagnosis will be defined as the index date and this group of patients will be defined as ET-to-PV cases.

Exclusion: None.

ClinicalTrials.gov NCT07203768